Paraneoplastic Autoimmunity Affecting the Nervous System

Brain Tumors: Practical Guide to Diagnosis and Treatment

Volumn , Issue , 2016, Pages 515-539

  Pittock, Sean J ^a   Lennon, Vanda A ^b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85178598184     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420019599-34     Document Type: Chapter

References (58)

1. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology I985; 35(4):538-543.
2. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncological profiles of patients seropositive for type 1 anti-neuronal nuclear autoantibodies. Neurology 1998; 50(3):652-657.
3. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29(3):241-251.
4. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2; Paraneoplastic accompaniments. Ann Neurol 2003; 53(5):580-597.
5. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: Marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50(3):301-311.
6. Graus F, Vincent A, Pozo-Rosich P, et al. Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmuno 2005; 165:166-171.
7. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49(2):146-154.
8. Folli F. Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328(8):546-551.
9. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: Paraneoplastic accompaniments. Ann Neurol 2005; 58(l):96-107.
10. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): Marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47(3):297-305.
11. Lennon VL. Calcium channel and related paraneoplastic disease autoantibodies. In: Peter JB, Schoenfeld Y, eds. Textbook of Autoantibodies. BV, The Netherlands: Elsevier Science Publishers, 1996:139-147.
12. Thirkill CE, Fitzgerald P, Sergott RC, et al. Cancer-associated retinopatiiy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 1989; 321(23):1589-1594.
13. Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurological disorders and small-cell lung cancer. Neurology 2004; 62(5):778-782.
14. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62(7):1177-1182.
15. Pozo-Rosich P, Clover L, Saiz A, et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54(4):530-533.
16. Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343(12):847-855.
17. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Can Res 2004; 10:7270-7275.
18. Peterson K, Rosenblum MK, Kotanides H, et al. Paraneoplastic cerebellar degeneration. A clinical, analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42(10):1931-1937.
19. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56(5):715-719.
20. Hetzel D, Stanhope CR, O’Neill BP, et al. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. Mayo Clin Proc 1990; 65(12):1558-1623.
21. Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratomas. Ann Neurol 2005; 58(4):594-604.
22. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127(Pt 8):1831-1844.
23. Bernal F, Shams’ili S, Rogas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 2003; 60(2):230-234.
24. Sillevis-Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342(l):21-27.
25. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124(Pt 6):1138-1148.
26. Sillevis Smitt P, Grefkens J, De Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249(6):745-753.
27. Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43(l):207-211.
28. Overeem S, Dalmau J, Bataller L, et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004; 62(l):138-140.
29. Vernino S, Tuite P. Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung cancer. Ann Neurol 2002; 51(5):625-630.
30. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54(l):38-50.
31. Shams’ili S, Grefkens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126(Pt 6):1409-1418.
32. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: a report of 3 cases. Arch Ophthalmol 1999; 117(4):471-477.
33. Harper CM, Lennon VA. Chapter: Lambert-Eaton syndrome. In: Kaminski HJ, ed. Current Clinical Neurology: Myasthenia Gravis and Related Disorders. Totowa, NJ: Humana Press, Inc., 2003:269-291.
34. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332(22):1467-1474.
35. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47(3):678-683.
36. Vincent A, Buckley C, Schott J, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127(Pt3):701-712.
37. Lennon VA. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997; 48(Suppl 5):S23-S27.
38. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123(Pt7):1481-1494.
39. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349(16):1543-1554.
40. Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 2000; 23(12):1800-1818.
41. Lambert EH, Lennon VA. Selected IgG rapidly induces Lambert-Eaton, myasthenic syndrome in mice: Complement independence and EMG abnormalities. Muscle Nerve 1988; 11(11):1133-1145.
42. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995; 37(Suppl 1):S74-S75.
43. Vernino S, Ermilov LG, Sha L, et al. Passive transfer of autoimmune antonomic neuropathy to mice. J Neurosci 2004; 24(32):7037-7042.
44. Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small cell lung carcinoma. Gastroenterol 1991; 100(1):137-142.
45. Ling CP, Pavesio C. Paraneoplastic syndromes associated with visual loss. Curr Opin Ophthalmol 2003; 14(6):426-432.
46. Griesmann GE, Harper CM, Lennon VA. Paraneoplastic myasthenia gravis and lung carcinoma: distinction from Lambert-Eaton syndrome and hypothesis of aberrant muscle acetylcholine receptor (AChR) expression. Muscle Nerve Suppl 1998; 7:S122.
47. Vernino S, Auger RG, Emslie-Smith, AM, et al. Myasthenia, thymoma, presynaptic antibodies and a continuum of neuromuscular hyperexcitability. Neurology 1999; 53(6):1233-1239.
48. Knowles CH, Lang B, Clover L, et al. A role for autoantibodies in some cases of acquired non-paraneoplastic gut dysmotility. Scan J Gastroenterol 2002; 37(2):166-170.
49. Galanis E, Frytak S, Rowland KM, et al. Neuronal autoantibody titers in the course of small cell lung carcinoma and platinum associated neuropathy. Cancer Immunol Immunother 1999; 48(2-3):85-90.
50. Verschakelen JA, De Wever W, Bogaert J. Role of computed tomography in lung cancer staging. Curr Opin Pulm Med 2004; 10(4):248-255.
51. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4(11):1321-1324.
52. Tavee J, Yu Z, O’Neill BP, et al. PCA-1 autoantibody of IgGl subclass predominates in patients with most severe paraneoplastic cerebellar degeneration. Neurology 2001; 56(S3):A415-416.
53. Giuntoli RL. Lu J, Kobayashi H, et al. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002; 8(3):922-931.
54. Graus F, Dalmau J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15(8):2866-2872.
55. Vernino S, O’Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-Oncology 2003; 6:55-62.
56. Stark E, Wurster U, Patzold U, et al. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 1995; 52(8):814-818.
57. Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatr 1996; 60(4):388-392.
58. Lundh H, Nilsson O, Rosen I. et al. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 1993; 88(2):136-140.